About this episode

Dr. Joel Kahn discusses the results of the Triumph-1 study on retatrutide and its implications for weight loss and cardiometabolic health.

In this episode of HeartDoc VIP, Dr. Joel Kahn breaks down the newly released — but not yet fully published — results from the highly anticipated Triumph-1 study on retatrutide, an investigational weight loss medication that's already generating major buzz in the cardiometabolic world. The reported weight loss results at 80 and 104 weeks are remarkable, with side effects appearing consistent with other medications in this class, including semaglutide and tirzepatide. Dr. Kahn discusses what's known so far, what questions still remain, and why the full peer-reviewed publication is so important before drawing final conclusions on risks and benefits. FDA approval may not be far away. Other topics in this packed episode include the troubling rise in fatal heart attacks among younger adults, a modified Mediterranean diet linked to lower diabetes risk, the connection between food preservatives and heart disease, atrial fibrillation in athletes, nitric oxide's role in brain health, fatty liver disease and cardiovascular risk, and how the American Heart Association's Life's Essential 8 score may predict diabetes risk in women. Thanks to Igennus for sponsoring this episode. Visit their…

People in this episode

Host: Dr. Joel Kahn

Topics covered

• weight loss
• cardiometabolic health
• medications
• heart disease
• diet
• diabetes risk

Keywords

• retatrutide
• weight loss
• Triumph-1 study
• cardiometabolic
• heart attacks
• Mediterranean diet
• diabetes risk
• atrial fibrillation
• nitric oxide
• fatty liver disease

Sponsors

Igennus

Mentioned in this episode

Organizations: American Heart Association

Products: retatrutide, semaglutide, tirzepatide

More episodes of Heart Doc VIP with Dr. Joel Kahn

• Episode 505: A Breakthrough in Cholesterol Care With an Oral PCSK9 Inhibitor · July 21, 2026 · 24 min
• Episode 504: Why Inflammation Matters for Patients with Lp(a) · July 14, 2026 · 31 min
• Episode 503: Supplements to Reverse Atherosclerosis: Follow-Up to The Proof · July 7, 2026 · 29 min
• Episode 502: Prozac (Fluoxetine) and Other Drugs That Injure Endothelium · June 30, 2026 · 25 min
• Episode 501: The Surprising Science of Gratitude and Heart Health · June 23, 2026 · 28 min
• Episode 500: The Long Path to Building an Integrative Cardiology Practice · June 16, 2026 · 31 min

Explore listener stats, chart rankings, contacts and more on the Heart Doc VIP with Dr. Joel Kahn podcast page.